78 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics plc
12 Aug 24
Adaptimmune Reports Q2 2024 Financial and Business Updates
7:05am
not repeated in 2024 and an increase in offsetting reimbursements, offset by an increase in other corporate costs due to an increase in accounting
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics plc
16 Jul 24
Departure of Directors or Certain Officers
4:30pm
required under applicable law including but not limited to Executive’s rights under COBRA. The Company may offset any amounts Executive owes the Company
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
. The Company may offset any amounts Executive owes the Company or its affiliates or subsidiaries against any amounts the Company owes Executive hereunder
8-K
EX-99.1
gom1y31f vae1sqjjq
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
8-K
EX-99.1
sta6h
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
8-K
EX-10.1
apxnuc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-99.1
1zid ncih
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
3j0t07065u4m
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
ehnw8m
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
1jbywm4x5uuxlwg6aj
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
z3exaa 5xz9ai
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
2s90u lycspx
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm